---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-275856"
form_type: "8-K"
ticker: "MDXG"
cik: "0001376339"
company_name: "MIMEDX GROUP, INC."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T12:54:57.947175+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MiMedx Q3 net sales $67.7M (+7.3% YoY); net loss widens to $8.4M; launches two surgical products

## Summary
- Net sales $67.7M, up 7.3% YoY; net loss $8.4M vs $2.3M loss prior year; adjusted EBITDA loss $0.7M vs gain $7.0M.
- Launched AXIOFILL and AMNIOEFFECT for surgical recovery; obtained Japan reimbursement for EPIFIX.
- Appointed Todd Newton interim CEO; new segment reporting for Wound & Surgical and Regenerative Medicine.
- Advanced KOA registrational study with FDA, including Type B RMAT meeting and CMC filings.

## SEC filing metadata
- accession: 0001193125-22-275856
- form_type: 8-K
- ticker: MDXG
- cik: 0001376339
- company_name: MIMEDX GROUP, INC.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1376339/000119312522275856/0001193125-22-275856-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1376339/000119312522275856/d399649d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-275856
- JSON: https://secwatch.observer/filing/0001193125-22-275856.json
- Plain text: https://secwatch.observer/filing/0001193125-22-275856.txt

## Key facts
- Earnings Releases
  MIMEDX GROUP, INC. reported third quarter ended September 30, 2022 results: revenue $67.7 million, net income $8.4 million, EPS $ (0.09 ).
  - Period: third quarter ended September 30, 2022
  - Revenue: $67.7 million
  - Net income: $8.4 million
  - EPS: $ (0.09 )
  - Result: reported results
  source text: Key Third Quarter 2022 Financial Metrics • Net sales of $67.7 million for third quarter 2022, compared to $63.1 million for the prior year period. • Net loss of $8.4 million for third quarter 2022, compared to a net loss of $2.3 million for the prior year period. • Adjusted EBITDA 1 loss of $0.7 million for third quarter 2022, compared to a gain of $7.0 million for the prior year period. Three Months Ended September 30, Nine Months Ended September 30, (in thousands) (in thousands) 2022 2021 2022 2021 Net sales $ 67,689 $ 63,074 $ 193,466 $ 191,206 Net loss (8,426 ) (2,339 ) (29,783 ) (12,500 ) EBITDA 1 (6,097 ) 41 (22,971 ) (4,302 ) Adjusted EBITDA 1 (724 ) 7,022 (3,402 ) 15,117 Net loss per common share - basic $ (0.09 ) $ (0.04 ) $ (0.31 ) $ (0.15 ) Net loss per common share - diluted $ (0.09 ) $ (0.04 ) $ (0.31 ) $ (0.15 )
  evidence_url: https://www.sec.gov/Archives/edgar/data/1376339/000119312522275856/0001193125-22-275856-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.